Clinical Trial Update: Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing prophylactic mesalamine to prevent colitis after treatment with ipilimumab and nivolumab in patients with advanced melanoma or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Rectal Cancer

Drugs mentioned

• Mesalamine (Mesalamine)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Immune-related Adverse Event, Diarrhea | Phase 2 | Status: RECRUITING